Marrone Bio Innovations, Inc. (MBII) Analysts See $-0.04 EPS

July 14, 2018 - By Eugene Smith

Marrone Bio Innovations, Inc. (NASDAQ:MBII) LogoInvestors sentiment increased to 5.5 in 2018 Q1. Its up 4.93, from 0.57 in 2017Q4. It is positive, as 1 investors sold Marrone Bio Innovations, Inc. shares while 1 reduced holdings. 6 funds opened positions while 5 raised stakes. 78.12 million shares or 565.72% more from 11.74 million shares in 2017Q4 were reported.
Vanguard Gp holds 0% of its portfolio in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 1.05M shares. Guggenheim Cap Limited owns 0% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 17,851 shares. Waddell And Reed Fincl holds 0.11% or 24.71 million shares. Primecap Co Ca, California-based fund reported 2.63 million shares. Northern Trust Corporation holds 31,936 shares or 0% of its portfolio. Ardsley Advisory Prtnrs has 1.91% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 10.35 million shares. Raymond James Ser Advisors invested in 0% or 11,061 shares. Ogorek Anthony Joseph Adv has invested 0% of its portfolio in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Blackrock has invested 0% of its portfolio in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Bluecrest Capital Mngmt owns 12,428 shares. Hanson Mcclain Incorporated holds 10,000 shares. Morgan Stanley has invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Barclays Public Ltd Liability Corp holds 0% or 20,200 shares. National Bank Of America Corporation De accumulated 0% or 10,102 shares. Geode Mgmt Limited Liability Corp reported 89,410 shares stake.

Since February 5, 2018, it had 1 buying transaction, and 0 sales for $5.00 million activity.

Analysts expect Marrone Bio Innovations, Inc. (NASDAQ:MBII) to report $-0.04 EPS on August, 13.They anticipate $0.21 EPS change or 84.00 % from last quarter’s $-0.25 EPS. After having $-0.04 EPS previously, Marrone Bio Innovations, Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.52% or $0.01 during the last trading session, reaching $1.92. About 174,618 shares traded. Marrone Bio Innovations, Inc. (NASDAQ:MBII) has risen 48.33% since July 14, 2017 and is uptrending. It has outperformed by 35.76% the S&P500.

Marrone Bio Innovations, Inc. provides bio pest management and plant health products primarily for agricultural and water markets in the United States and internationally. The company has market cap of $212.10 million. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. It currently has negative earnings. The company's products include Regalia, a plant extract fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants.

More important recent Marrone Bio Innovations, Inc. (NASDAQ:MBII) news were published by: Globenewswire.com which released: “Marrone Bio Innovations Joins the Russell 2000 Index” on June 25, 2018, also Nasdaq.com published article titled: “Marrone Bio Innovations to Host Virtual Roadshow Webinar on July 26th, 2018”, Bizjournals.com published: “Why Marrone Bio is sponsoring a cannabis-growing competition” on June 20, 2018. More interesting news about Marrone Bio Innovations, Inc. (NASDAQ:MBII) was released by: Investorideas.com and their article: “(NASDAQ: $MBII) News: Grandevo® CG and Venerate® CG for Pest Insect and Mite Control Cleared for Use on …” with publication date: June 28, 2018.

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.